Raphi Levy Sells 2,871 Shares of Alpha Tau Medical (NASDAQ:DRTS) Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 2,871 shares of Alpha Tau Medical stock in a transaction on Friday, August 21st. The stock was sold at an average price of $15.00, for a total transaction of $43,065.00. Following the sale, the chief financial officer directly owned 90,180 shares in the company, valued at $1,352,700. This trade represents a 3.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Tuesday, August 11th, Raphi Levy sold 17,730 shares of Alpha Tau Medical stock. The shares were sold at an average price of $14.00, for a total transaction of $248,220.00.
• On Monday, July 6th, Raphi Levy sold 2,270 shares of Alpha Tau Medical stock. The shares were sold at an average price of $14.00, for a total value of $31,780.00.
• On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.00, for a total value of $232,349.00.
• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.02, for a total value of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total value of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $11.00, for a total value of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Stock Up 0.3%

Shares of Alpha Tau Medical stock traded up $0.05 on Tuesday, hitting $14.75. 116,827 shares of the company’s stock traded hands, compared to its average volume of 586,023. Alpha Tau Medical Ltd. has a 52-week low of $3.18 and a 52-week high of $15.02. The company has a quick ratio of 7.79, a current ratio of 11.09 and a debt-to-equity ratio of 0.15. The stock has a market cap of $1.33 billion, a P/E ratio of -14.12 and a beta of 1.17. The firm’s 50-day moving average is $12.53 and its 200 day moving average is $9.68.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.36). The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.14 million. Equities analysts anticipate that Alpha Tau Medical Ltd. will post -0.92 earnings per share for the current year.

Wall Street Analyst Weigh In

DRTS has been the topic of a number of recent analyst reports. HC Wainwright upped their target price on shares of Alpha Tau Medical from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Benchmark reissued a “buy” rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Zacks Research upgraded Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. LADENBURG THALM/SH SH upped their price objective on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Finally, Barclays increased their target price on Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Thursday, June 4th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $12.80.

Institutional Investors Weigh In On Alpha Tau Medical

Institutional investors have recently modified their holdings of the business. Trifecta Capital Advisors LLC bought a new position in Alpha Tau Medical in the fourth quarter worth about $48,000. Everhart Financial Group Inc. bought a new position in shares of Alpha Tau Medical during the second quarter valued at approximately $126,000. Envestnet Asset Management Inc. acquired a new stake in shares of Alpha Tau Medical during the 3rd quarter worth approximately $62,000. Principal Financial Group Inc. acquired a new stake in shares of Alpha Tau Medical during the 1st quarter worth approximately $132,000. Finally, Bank of America Corp DE lifted its holdings in shares of Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after purchasing an additional 21,677 shares during the last quarter. Institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.